Modulated Neuroprotection in Unresponsive Wakefulness Syndrome after Severe Traumatic Brain Injury.

Daia C, Scheau C, Spinu A, Andone I, Popescu C, Toader C, Bumbea AM, Verenca MC, Onose G

Brain sciences6 Aug 2021Cited by 5 (Europe PMC)

PMID34439663PMCIDPMC8394505DOI10.3390/brainsci11081044PepBankPUB-34439663

Summary

BackgroundWe aimed to assess the effects of modulated neuroprotection with intermittent administration in patients with unresponsive wakefulness syndrome (UWS) after severe traumatic brain injury (TBI).MethodsRetrospective analysis of 60 patients divided into two groups, with and without neuroprotective treatment with Actovegin, Cerebrolysin, pyritinol, L-phosphothreonine, L-glutamine, hydroxocobalamin, alpha-lipoic acid, carotene, DL-α-tocopherol, ascorbic acid, thiamine, pyridoxine, cyanocobalamin, Q 10 coenzyme, and L-carnitine alongside standard treatment.Main outcome measuresGlasgow Coma Scale (GCS) after TBI, Extended Glasgow Coma Scale (GOS E), Disability Rankin Scale (DRS), Functional Independence Measurement (FIM), and Montreal Cognitive Assessment (MOCA), all assessed at 1, 3, 6, 12, and 24 months after TBI.ResultsPatients receiving neuroprotective treatment recovered more rapidly from UWS than controls (p = 0.007) passing through a state of minimal consciousness and gradually progressing until the final evaluation (p = 0.000), towards a high cognitive level MOCA = 22 ± 6 points, upper moderate disability GOS-E = 6 ± 1, DRS = 6 ± 4, and an assisted gait, FIM =101 ± 25. The improvement in cognitive and physical functioning was strongly correlated with lower UWS duration (-0.8532) and higher GCS score (0.9803).ConclusionModulated long-term neuroprotection may be the therapeutic key for patients to overcome UWS after severe TBI.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

01HumanNot a test of Cerebrolysin aloneObservational studyEfficacy outcome
In patients after severe traumatic brain injury, the multi-agent regimen containing Cerebrolysin was linked to faster recovery from unresponsive wakefulness than control.
In plain wordsIn patients after severe brain injury, the regimen containing Cerebrolysin was linked to faster recovery from unresponsive wakefulness than control.
Peptide
Cerebrolysin
Outcome
IncreaseRecovery from unresponsive wakefulness
Study
n = 60
Comparator
No neuroprotective treatment
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
p value for recovery from UWS
0.007
neuroprotective regimen containing Cerebrolysin versus controls
Source sentences
Summary
Patients receiving neuroprotective treatment recovered more rapidly from UWS than controls (p = 0.007)
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective analysis of 60 patients divided into two groups, with and without neuroprotective treatment with Actovegin, Cerebrolysin, pyritinol
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3443966301
02HumanNot a test of Cerebrolysin aloneObservational studyEfficacy outcome
In patients after severe brain injury, the regimen containing Cerebrolysin was linked to cognitive progression to MOCA 22 ± 6 points.
In plain wordsIn patients after severe brain injury, the regimen containing Cerebrolysin was linked to cognitive progression to MOCA 22 ± 6 points.
Peptide
Cerebrolysin
Outcome
IncreaseMOCA cognitive score
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Measurements
MOCA
22 points
final evaluation; reported as 22 ± 6
MOCA reported ± term (uncertainty type not stated)
6 points
neuroprotective treatment group, final evaluation
Source sentences
Summary
passing through a state of minimal consciousness and gradually progressing until the final evaluation (p = 0.000), towards a high cognitive level MOCA = 22 ± 6 points
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective analysis of 60 patients divided into two groups, with and without neuroprotective treatment with Actovegin, Cerebrolysin, pyritinol
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3443966302
03HumanNot a test of Cerebrolysin aloneObservational studyEfficacy outcome
In patients after severe brain injury, the regimen containing Cerebrolysin was associated with final GOS-E 6 ± 1.
In plain wordsIn patients after severe brain injury, the regimen containing Cerebrolysin was associated with final GOS-E 6 ± 1.
Peptide
Cerebrolysin
Outcome
Not applicableGOS-E disability score
Study
n: not reported in source
Outcome group
Exercise and physical function · Nervous system and cognition
Measurements
GOS-E
6 points
final evaluation
GOS-E reported ± term (uncertainty type not stated)
1
neuroprotective treatment group, final evaluation
Source sentences
Summary
upper moderate disability GOS-E = 6 ± 1
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective analysis of 60 patients divided into two groups, with and without neuroprotective treatment with Actovegin, Cerebrolysin, pyritinol
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3443966303
04HumanNot a test of Cerebrolysin aloneObservational studyEfficacy outcome
In patients after severe brain injury, the regimen containing Cerebrolysin was associated with final DRS 6 ± 4.
In plain wordsIn patients after severe brain injury, the regimen containing Cerebrolysin was associated with final DRS 6 ± 4.
Peptide
Cerebrolysin
Outcome
Not applicableDRS disability score
Study
n: not reported in source
Outcome group
Exercise and physical function · Nervous system and cognition
Measurements
DRS
6
final evaluation; reported as 6 ± 4
DRS reported ± term (uncertainty type not stated)
4
neuroprotective treatment group, final evaluation
Source sentences
Summary
DRS = 6 ± 4
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective analysis of 60 patients divided into two groups, with and without neuroprotective treatment with Actovegin, Cerebrolysin, pyritinol
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3443966304
05HumanNot a test of Cerebrolysin aloneObservational studyEfficacy outcome
In patients after severe brain injury, the regimen containing Cerebrolysin was associated with assisted gait and FIM 101 ± 25.
In plain wordsIn patients after severe brain injury, the regimen containing Cerebrolysin was associated with assisted gait and FIM 101 ± 25.
Peptide
Cerebrolysin
Outcome
Not applicableFIM functional independence
Study
n: not reported in source
Outcome group
Exercise and physical function · Nervous system and cognition
Measurements
FIM
101
final evaluation; reported as 101 ± 25
FIM reported ± term (uncertainty type not stated)
25
neuroprotective treatment group, final evaluation
Source sentences
Summary
and an assisted gait, FIM =101 ± 25.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective analysis of 60 patients divided into two groups, with and without neuroprotective treatment with Actovegin, Cerebrolysin, pyritinol
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3443966305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.